

Endocrine Abstracts

May 2016 Volume 41
ISSN 1479-6848 (online)

18th European Congress of
Endocrinology 2016

28–31 May 2016, Munich, Germany



published by
bioscientifica

Online version available at
www.endocrine-abstracts.org



18th European Congress of Endocrinology

28–31 May 2016

EDITORS

The abstracts were marked by the Abstract marking Panel selected by the programme Organising Committee

Programme Organising Committee (POC)

Ipo Huhtaniemi (Finland/UK) Chair, Programme Organising Committee (POC)
Robin Peeters (The Netherlands) Co-chair, Programme Organising Committee (POC)
Ewa Rajpert-de Meys (Denmark) Co-chair, Programme Organising Committee (POC)
Günter Stalla (Germany)

Laura Fugazzolla (Italy)
Tsvetalina Tankova (Bulgaria)
William Rainey (USA)
Constantine Stratakis (USA)
Sebastian Schmid (Germany)
Geert Carmeliet (Belgium)
Christina Kanaka-Gantenbein (Greece)

Nadine Binart (France)
Filip Gabalec (Czech Republic)
Bulent Yildiz (Turkey)
Marjia Pfeifer (Slovenia)
Jerome Bertherat (France)

Local Organising Committee (LOC)

Gunter Stalla (Germany)
Christoph Auernhammer (Germany)
Felix Beuschlein (Germany)
Michael Buchfelder (Germany)
Helmuth GüntherDörr (Germany)

Jörg Gromoll (Germany)
Martin Grüssendorf (Germany)
Martin Reincke (Germany)
Vanadin Seifert-Klauss (Germany)
Christine Spitzweg (Germany)

Marily Theodoropoulou (Germany)
Matthias Tschöp (Germany)
Günter Höfle (Austria)
Emanuel Christ (Switzerland)

Abstract Marking Panel

J Achermann UK
M Alevizaki Greece
G Assié France
S Aylwin UK
S Babajko France
K Badenhoop Germany
D Bassett UK
E Baudin France
A Beckers Belgium
P Beck-Peccoz Italy
J Bertherat France
F Beuschlein Germany
B Bilinska Poland
M Blucher Germany
K Boelaert UK
A Boelen The Netherlands
R Bouillon Belgium
J-P Bourguignon Belgium
G Brabant Germany
M L Brandi Italy
K Briot France
G Brunetti Italy
C Buchanan UK
S Cannavo Italy
J Cap Czech Republic
JS Carroll UK
J Castano Spain
P Chanson France
K Chatterjee UK
I Chiodini Italy
J Chowen Spain
T Coll UK
D Cuthbertson UK
K Dahlman-Wright Sweden
C Daousi UK
M Dattani UK
C Dayan UK
W de Herder Netherlands
E de Koning The Netherlands
B Demeneix France
M Dentice Italy
W Dhillon UK
G Di Dalmazi Germany
E Diamanti-Kandarakis Greece
F Dotto Italy
J Drouin Canada
L Duntas Greece
G Eisenhofer Germany
F Fallo Italy
P Farahani Canada
S Farooqi UK

M Fassnacht Germany
R Feelders The Netherlands
U Feldt-Rasmussen Denmark
F Flamant France
E Fliers The Netherlands
C Fluck Germany
C Follin Sweden
S Franks UK
W Fraser UK
J Frystyk Denmark
L Fugazzolla Italy
D Fuhrer Germany
F Gabalec Czech Republic
R Gärtner Germany
A-P Gimenez-Roqueplo France
F Giorgino Italy
J Gomez-Ambrosi Spain
R Granata Italy
J Gromoll Germany
A Grossman UK
S Hahner Germany
R Hampl Czech republic
M Heikinheimo Finland
S Herzig Germany
M Hewison UK
M Hewison UK
A Hoellich Germany
C Hofig Sweden
L Hofland Netherlands
W Hogler UK
I Huhtaniemi UK
P Igaz Hungary
Erica Isenovic Serbia
M-L Jaffrain-Rea Italy
B Jarzab Poland
C Jazdzewski Poland
D Jezova Slovakia
A Juul Denmark
A Kalsbeek Netherlands
G Kaltsas Greece
C Kanaka-Gantenbein Greece
M Keil USA
F Kelestimir Turkey
R Kineman USA
M Korbonits UK
N Krone UK
M Krsek Czech Rep
H Krude Germany
M Laan Germany
M Laan Switzerland
P Lakatos Hungary

E Lalli
J Laven The Netherlands
G Lavery UK
S Lebouleux France
J Leger France
T Links The Netherlands
S Llahana UK
A Luger Austria
RM Luque Spain
M Luster Germany
M Maggi Italy
M Mannelli Italy
F Mantero Italy
G Mastorakis Greece
E Mathiesen Denmark
C McCabe UK
R Mitchell UK
J Mittag Germany
L Morin-Papunen Finland
N Morton UK
A Mukherjee UK
E Nagy Hungary
J Newell-Prize UK
D O'Halloran Ireland
U Pagotto Italy
JJ Palvimo Finland
S Papopolous Netherlands
S Pearce UK
R Peeters The Netherlands
L Persani Italy
M Pfeifer Slovenia
T Pieber Austria
N Pitteloud Switzerland
M Poutanen Finland
D Power Portugal
V Prevot France
S Radian UK
N Rahman Finland
B Rainey USA
T Raiivo Finland
E Rajpert-De Meys Denmark
G Raverot France
M Reincke Germany
S Rice UK
I Robert UK
M Robledo Spain
P Rodien France
G Roman Romania
H Romijn The Netherlands
C Ronchi Italy
R Ross UK

GP Rossi
M Ruchala Poland
E Rutten Belgium
S Sanlioglu Turkey
P Saunders UK
S Schmid Germany
P Schöffski Belgium
J Schopohl Germany
M Schott Germany
U Smith Sweden
A Spada
G Stalla Germany
E Stener-Victorin Sweden
C Stratakis USA
T Tankova Bulgaria
M Tena-Sempere
M Terzolo
M Theodoropoulou Germany
P Thompson UK
C Thompson Ireland
V Tillmann Estonia
H Timmers The Netherlands
J Toppari Finland
M Toth Hungary
S Tsagarakis Greece
M Tzanela Greece
E Valassi Spain
E van den Akker Netherlands
J van der Eck The Netherlands
AJ van der Lelij Netherlands
W van Hul Belgium
H van Leeuwen The Netherlands
B Verges France
E Visser The Netherlands
J Visser The Netherlands
P Vitti Italy
V Volke Estonia
Tracy Williams Italy
T Williams UK
Z Wu Germany
P Yeoh UK
J Young France
M Zatelli Italy
M-C Zennaro France

SPONSORS

The ESE would like to thank its Corporate Members and the ECE 2016 sponsors

ECE Corporate Members

- Chiasma
- Eli Lilly
- Ipsen
- Laboratoire HRA Pharma
- Merck Serono
- Novartis Pharmaceuticals
- Novo Nordisk
- Pfizer
- Sandoz International GmbH
- Shire Services BVBA
- Strongbridge Biopharma

Gold Sponsors

Ipsen
Novartis

Bronze Sponsors

Pfizer



ESE Office

Euro House
22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact:
Tel:
Fax:
E-mail:
Web site:

Andrea Davis
+44 (0)1454 642247
+44 (0)1454 642222
info@euro-endo.org
www.es-hormones.org



ECE 2016 Secretariat

Bioscientifica Ltd
Euro House, 22 Apex Court
Woodlands
Bradley Stoke
Bristol BS32 4JT, UK

Contact:
Tel:
Fax:
E-mail:
Website:

Niki Cripps
+44 (0)1454 640467
+44 (0)1454 642222
ece2016@bioscientifica.com
http://www.bioscientifica.com

CONTENTS

18th European Congress of Endocrinology 2016

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The European Journal of Endocrinology Prize Lecture	EJE1
The Geoffrey Harris Prize Lecture	GH1
Clinical Endocrinology Trust Award & Lecture	CETL1

PLENARY LECTURES

PRRT, NETTER-1, and the new Era	PL1
Endocrine disruptors and the thyroid (<i>Endorsed by Endocrine Connections</i>)	PL2
Testosterone trials	PL3
Gut microbiota, inflammation and metabolism (<i>Endorsed by Endocrine Connections</i>)	PL4
Insulin signalling and action	PL5
Bionic pancreas	PL6

SYMPOSIA

Thyroid and Pregnancy	S1.1–S1.3
Mixtures, medicines and diet, where now for endocrine disrupting compounds? (<i>Endorsed by Endocrine Connections</i>)	S2.1–S2.3
Senescence and plasticity in the anterior pituitary	S3.1–S3.3
How to diagnose endocrine disease in obese patients? (<i>Endorsed by the European Journal of Endocrinology</i>)	S4.1–S4.3
Adrenal incidentaloma guidelines	S5.1–S5.7
Characterization and treatment of thyroid cancer	S6.1–S6.3
The chronic syndromes of patients with cured pituitary diseases (<i>Endorsed by the European Journal of Endocrinology</i>)	S7.1–S7.3
Primary aldosteronism	S8.1–S8.3
Bone marrow adipose tissue - A "novel" functionally active fat depot	S9.1–S9.3
Late Breaking News Session	S10.1–S10.3
New Developments in subclinical thyroid disease	S11.1–S11.3
Novel insights of disorders in pubertal timing	S12.1–S12.3
Management of Cushing's syndrome	S13.1–S13.3
Hot topics on vitamin D	S14.1–S14.3
In the rhythm of EYES: Let's dance!	S15.1–S15.3
Thyroid nodules	S16.1–S16.3
Genetics and epigenetics of testicular failure	S17.1–S17.3
Neuroendocrine tumours: new findings, classification and targeted management	S18.1–S18.3
Brown adipose tissue - a burning issue (<i>Endorsed by Endocrine Connections</i>)	S19.1–S19.3
Hitchhiker's guide to the microcosmos of GPCRs	S20.1–S20.3
An update on hyperparathyroidism	S21.1–S21.3
New mechanisms to induce and protect from ovarian insufficiency	S22.1–S22.3
Indications of incretin based therapies	S23.1–S23.3
Endocrine neoplasias: new associations (<i>Endorsed by the European Journal of Endocrinology</i>)	S24.1–S24.3
What's new and exciting in nuclear receptor action?	S25.1–S25.3
An update on bone homeostasis and osteoporosis (<i>Endorsed by the European Journal of Endocrinology</i>)	S26.1–S26.3
Why do we gain weight; homeostasis and rewards of ingestive behaviour	S27.1–S27.3
Adrenal Insufficiency: Causes and management	S28.1–S28.3
New insights into the pathogenesis of PCOS	S29.1–S29.3
Disorders of development and function of neurohypophysis	S30.1–S30.3

NEW SCIENTIFIC APPROACHES NSA1–NSA5

DEBATE

The use of NSAIDs in endocrine cancers: the case of Celecoxib D1.1–D1.3
 Should we treat subclinical Cushing’s syndrome? D2.1–D2.2
 Strengths and weaknesses of hormone immunoassays and mass spectrometry: what the clinician should know D3.1–D3.2
 Are we ready for pharmacological therapy of obesity? D4.1–D4.2

MEET THE EXPERT SESSIONS MTE1–MTE10

ORAL COMMUNICATIONS

Adrenal - Basic & Clinical OC1.1–OC1.5
 Receptors & Signalling OC2.1–OC2.5
 Diabetes prediction & complications OC3.1–OC3.5
 Thyroid - Clinical OC4.1–OC4.5
 Neuroendocrinology OC5.1–OC5.5
 Diabetes therapy & complications OC6.1–OC6.5
 Cardiovascular endocrinology OC7.1–OC7.5
 Thyroid - Translational OC8.1–OC8.5
 Endocrine Tumours OC9.1–OC9.5
 Reproduction & Endocrine Disruption OC10.1–OC10.5
 Bone & Calcium Homeostasis OC11.1–OC11.5
 Obesity OC12.1–OC12.5
 Pituitary Clinical OC13.1–OC13.5
 Thyroid Cancer OC14.1–OC14.5

GUIDED POSTERS

Adrenal GP1–GP10
 Adrenal GP11–GP20
 Adrenal GP21–GP30
 Bone & Calcium Homeostasis GP31–GP40
 Bone & Calcium Homeostasis GP41–GP50
 Cardiovascular endocrinology GP51–GP59
 Clinical Case Reports GP60–GP69
 Diabetes GP70–GP79
 Diabetes GP80–GP89
 Diabetes GP90–GP99
 Endocrine Nursing GP100–GP108
 Endocrine Tumours GP109–GP118
 Neuroendocrinology GP119–GP128
 Obesity GP129–GP138
 Paediatric Endocrinology & Development GP139–GP148
 Pituitary - Clinical GP149–GP158
 Pituitary - Clinical GP159–GP168
 Receptors & Signalling GP169–GP178
 Reproduction & Endocrine Disruption GP179–GP188
 Thyroid - Basic GP189–GP198
 Thyroid - Translational & Clinical GP199–GP208
 Thyroid - Translational & Clinical GP209–GP218
 Thyroid Cancer GP219–GP228
 Thyroid Cancer GP229–GP238

EPOSTER PRESENTATIONS

Adrenal cortex (to include Cushing’s) EP1–EP83
 Adrenal medulla EP84–EP96
 Bone & Osteoporosis EP97–EP134
 Calcium and Vitamin D metabolism EP135–EP194
 Cardiovascular Endocrinology and Lipid Metabolism EP195–EP245
 Clinical case reports - Pituitary/Adrenal EP246–EP326

Clinical case reports - Thyroid/Others	EP327-EP396
Developmental endocrinology	EP397-EP400
Diabetes (to include epidemiology, pathophysiology)	EP401-EP483
Diabetes complications	EP484-EP537
Diabetes therapy	EP538-EP581
Endocrine Disruptors	EP582-EP587
Endocrine Nursing	EP588
Endocrine tumours and neoplasia	EP589-EP656
Female Reproduction	EP657-EP698
Growth hormone IGF axis - basic	EP699-EP709
Male Reproduction	EP710-EP727
Neuroendocrinology	EP728-EP770
Nuclear receptors and Signal transduction	EP771-EP776
Obesity	EP777-EP844
Paediatric endocrinology	EP845-EP852
Pituitary - Basic	EP853-EP869
Pituitary - Clinical	EP870-EP952
Steroid metabolism + action	EP953-EP965
Thyroid (non-cancer)	EP966-EP1085
Thyroid cancer	EP1086-EP1166

INDEX OF AUTHORS

Eposter Presentations

of cardio-metabolic diseases. The aim of this study was to search for any difference of the oxidative stress parameters between in patients with hypogonadism and healthy controls.

Materials and Methods

Thirty eight male patients with congenital hypogonadotropic hypogonadism (CHH) (mean age 21.7 ± 1.6 years) and 44 body mass index (BMI) matched healthy male subjects (mean age 22.3 ± 1.4 years) were enrolled. The demographic parameters, homeostatic model assessment of insulin resistance (HOMA-IR) and oxidative stress parameters such as superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx) and malondialdehyde (MDA) were measured in patients and healthy controls.

Results

When compared to the healthy controls, triglycerides ($p=0.02$), insulin, HOMA-IR, catalase and MDA levels ($P < 0.001$ for all) were significantly higher, and the HDL cholesterol ($P=0.04$), total testosterone, FSH, LH and GPx levels ($P < 0.001$ for all) were significantly lower in patients with CHH. There were significant correlations between the total testosterone levels and catalase ($r = -0.33$ $P=0.01$), GPx ($r=0.36$ $P=0.007$) and MDA ($r = -0.47$ $P < 0.001$) levels.

Conclusions

The results of this study show that young and treatment naïve patients with hypogonadism have increased oxidative stress related parameters such as serum catalase and MDA levels. There is significant correlation between oxidative stress parameters and testosterone levels. Prospective, randomized, controlled studies with larger number of cases are needed to prove the relationship between oxidative stress and increased cardio-metabolic risk in hypogonadism.

DOI: 10.1530/endoabs.41.EP716

EP717

Delay in the onset of male puberty: role of mutations in luteinizing hormone-beta gene

Ghazala Shaheen¹, Maleeha Akram¹, Qiaser Mansoor², Muhammad Ismail², Osama Ishtiaq³, Sarwat Jahan⁴, Afzaal Ahmed Naseem¹, Mazhar Qayyum¹ & Syed Shakeel Raza Rizvi¹

¹Department of Zoology, Pir Mehr Ali Shah Arid Agriculture University Rawalpindi, Rawalpindi, Pakistan; ²Institute of Biomedical and Genetic Engineering, (IBGE), Islamabad, Pakistan; ³Department of Endocrinology, Shifa International Hospital, Islamabad, Pakistan; ⁴Department of Animal Sciences, Quaid-i-Azam University, Islamabad, Pakistan.

The reawakening of hypothalamo-pituitary-gonadal axis at puberty is influenced by a number of hormonal and genetic factors along with certain environmental cues. In boys, puberty is initiated at around 9 years of age as plasma concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone (T) begin to rise leading to development of secondary sex characteristics. The absence of signs of sexual maturation at the age of 14/15 years is regarded as delayed puberty. One of the main causes of delay in puberty is hypogonadotropic hypogonadism (HH), characterized by low LH, FSH and T secretion, resulting in absent or impaired sexual development. This study examined the endocrine and genetic basis of pubertal delay in boys. Blood samples were obtained from 30 boys of delayed pubertal development and 30 age matched controls. The plasma concentration of growth hormone (GH), LH, FSH and T were determined using ELISA. Based on low plasma concentrations of GH, LH, FSH and T, genetic analysis was performed for determining possible mutations in TACR3 and LH- β genes. TACR3 is expressed in the hypothalamus, whereas LH- β is synthesized by pituitary gonadotropes. One mutation, H148L, of TACR3 and two mutations, G56D and G122S, of LH- β were screened. DNA was extracted from blood samples of both groups by organic method, primers of exons of TACR3 and LH- β splice sites were designed and PCR-RFLP method was employed for analysis. The mutations H148L of TACR3 and G56D of LH- β were not found in any group, whereas the PCR product of LH- β digested by enzyme Eco01091 gave bands of 3 different genotypes in HH boys, GG (93.33%), GA (3.33%) and AA (3.33%). Thus, one heterozygous G122S mutation in one and one homozygous G122S mutation in another patient were identified. In conclusion, homozygous G122S mutation may cause pubertal delay in our local population.

DOI: 10.1530/endoabs.41.EP717

EP718

Is Testosterone (T) treatment safe and effective in men with HIV infection? A meta-analysis

Daniele Santi¹, Giovanni Guaraldi³, Giovanni Corona² & Vincenzo Rochira¹

¹Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia and Azienda USL of Modena, Modena, Italy, ²Endocrinology Unit, Medical Department, Azienda USL of Bologna, Maggiore-Bellaria Hospital, Bologna, Italy; ³Metabolic Clinic, Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences for Adults and Children, Clinic of Infectious Diseases, University of Modena and Reggio Emilia, Modena, Italy.

Background

Prevalence of hypogonadism is high (30%) in men with HIV. In these patients T treatment (TT) is currently used mainly to counteract wasting syndrome and/or HIV-related lipodystrophy, irrespective of patients' serum T. However, its effect and safety in HIV-infected men is still not completely known.

Aim

To investigate both beneficial and adverse effects related to TT in HIV-infected men using a meta-analytic approach.

Methods

An extensive MEDLINE search was performed using 'PubMed' with the following key-words: 'HIV' and: 'hypogonadism', 'TT', 'T', 'androgens' or 'sex steroids' from 1946 to April 2015. Meta-analysis included 19 placebo-controlled-clinical trials evaluating TT in HIV patients and was conducted according to PRISMA statement using RevMan.

Results

All 19 trials evaluated the effect of TT on body weight on a total of 952 subjects (TT group: 557; placebo group: 395). Patients' gonadal status was often not reported and most of patients were presumably eugonadal. All data are shown as standardized mean and Confidence Interval (CI). TT significantly improved total lean body mass (1.44 [0.82–2.07], $P < 0.001$), total body weight (0.99 [0.25–1.72], $P=0.008$) and fat free mass (1.48 [0.85–2.12], $P < 0.001$). This improvement is characterized by higher heterogeneity ($I^2=84\%$, 88% , and 60% , respectively). Conversely, no beneficial effects were seen on total fat mass (-0.17 [-1.58 – 1.25], $P=0.820$). TT was associated with an increased incidence of minor adverse events (OR=1.50[1.11–2.01], $P=0.008$) and increased mean serum PSA (0.10 ng/mL, [0.03–0.17], $P=0.007$). No change in hemoglobin (0.39 g/dL, [-0.29 – 1.07], $P=0.260$) was seen.

Conclusions

Our study suggests that TT in HIV-infected men is effective in improving body composition (increase in lean body mass), although the incidence of general adverse events is higher than in the placebo group. However, studies show a highest variability and the real benefits of TT in HIV-infected men remains still to be established.

DOI: 10.1530/endoabs.41.EP718

EP719

Aluminium oxide nanoparticles-induced spermatotoxicity, oxidative stress and changes in reproductive hormones and testes histopathology in male rats: Possible protective effect of glutathione

Mokhtar Ibrahim Yousef¹, Thanaa I. Shalaby² & Adil A. Kareem¹

¹Department of Environmental Studies, Institute of Graduate Studies and Research, Alexandria University, 163 Horreya Avenue, Chatby 21526, P.O. Box 832, Alexandria, Egypt; ²Department of Medical Biophysics, Medical Research Institute, Alexandria University, Alexandria, Egypt.

There is a rising use of Aluminium oxide nanoparticles (Al_2O_3 NPs) in many branches of industry and personal care products. Because of these uses, their impact on the environment must be considered and investigated. Almost nothing is known about the effects of Al_2O_3 NPs on semen quality and reproductive hormones. Possible mechanisms for the cytotoxicity of Al_2O_3 NPs are still being discussed, but oxidative stress may be responsible for their effect. Therefore, the objective of this study was thus to know the capability of glutathione as antioxidant agent against the effects of Al_2O_3 NPs on sperm parameters, testosterone, FSH, LH, steroid enzymes, histological changes, lipid peroxidation and antioxidant enzymes in male rats. Animals were divided into four groups, group 1 was used as control, group 2 was treated orally with glutathione (100 mg/kg BW), group 3 was treated intraperitoneally (IP) with aluminum oxide nanoparticles (70 mg/kg BW; < 50 nm), group 4 was treated with aluminum oxide nanoparticles plus glutathione. Rats were administered their respective doses every day for 77 day. Results showed that Al_2O_3 NPs decreased final body weight, body weight gain, relative testes and epididymis weights, sperm count,

Author Index

- Aalaa, M GP104 & GP106
 Aas, C OC8.4
 Abad, A EP1118
 Abaza, D EP515
 Abbasoglu, O EP646
 Abdallah, NB EP1042,
 EP457 & GP101
 abdalrahman, I EP523
 AbdelRaof, Y EP190
 Abdelsalam, M GP80
 Abdelsalam, MM EP1004
 AbdelWahab, E EP190
 Abdul Salam Ahmed, M
 EP759
 Abellán, P EP1010
 & EP1011
 Åberg, D EP732
 Aberer, F EP546
 Abid, A EP531
 Abid, M EP1007
 Abitbol, J GP28
 Abraham, P EP932
 Abrosimov, A EP1130
 Abs, R EP700
 Abuin Fernandez, J EP474
 Abusahmin, H EP431
 Abushady, MM EP1004
 Acerini, C EP14
 Ach, K EP1059, EP179
 & EP306
 Achenbach, H GP14
 Acikalın, M EP310
 Acosta-Calero, C EP225
 & EP93
 Adamczewski, Z EP1023
 Adamidou, F EP1121,
 EP1154, EP30, EP44
 & EP57
 Adams, JE GP33
 Adamska, A EP683 &
 GP183
 Adamski, J GP29
 Adas, M EP968, EP1001
 & EP1006
 Adatepe, T OC3.5
 Adaway, J GP178
 Ademoglu, E EP1028,
 EP1029, EP629
 & EP788
 Ademoglu, EN EP181,
 EP524, EP696
 & EP952
 Adibi, H GP104
 Adolf, C EP5
 Adorini, L EP201 & GP56
 Adorno, A EP1144
 Affam, D EP187
 Aflorei, ED EP854 & OC5.1
 Afonso, EP334
 Afzal, N EP228
 Agapito, A EP643
 & EP925
 Agarwal, A EP1044
 & EP1112
 Agarwal, G EP1044
 & EP1112
 Agarwal, S EP84
 Aggarwal, A EP343
 Aggarwal, V EP343
 Aghaei, M EP488
 Aghajanova, Y EP549
 & EP848
 Aglony, M GP148
 Agudo-Macazaga, M
 GP199
 Aguiar, NDMM EP392
 Aguilar, M EP415
 & EP861
 Aguilar-Diosdado, M
 EP558, EP801, EP832
 & GP76
 Aguilera-Tejero, E GP144
 Aguirre Sanchez-Covisa,
 M GP97
 Ahbab, S EP161, EP456,
 EP47 & EP478
 Ahci, S EP1067
 Ahmad, S EP363 & EP83
 Ahmed, I GP80
 Ahmed, M EP647
 Ahmed Naseem, A EP228
 & EP519
 Ahmet Ay, S EP307,
 EP320 & EP405
 Ahn, C EP402 & EP962
 Ahn, HJ EP198
 Aho, L-S EP870
 Ahtiainen, P EP138
 Ai Kang, S EP402 & EP962
 Aicha, B EP815
 Aigelsreiter, A EP232
 Aissa, A EP948
 Aizic, A EP1090
 Ajabnoor, G EP844B
 Ajduk, M EP836
 Ajmi, H GP84
 Akalm, A EP357
 & EP971
 Akarsu, E GP166
 Akay, E EP78
 Akay, F OC6.1
 Akbarov, Z EP537
 Akbarova, Y EP400B
 Akca, EP480
 Åkerman, A-K GP167
 Akdemir, NU EP178
 Akin, F EP1078, EP252,
 EP778, EP795
 & EP821
 Akkas, N EP105
 Akkurt, A EP1111
 Akkus, G EP18
 Akli Ayoub, M OC10.2
 Akram, M EP228, EP468,
 EP519 & EP717
 Aksyonova, E EP798
 Aktar, MK EP660
 Aktimur, R EP806
 Akturk, M EP72
 & EP173
 Akulkina, L EP34
 Akyay, OZ EP1030, EP105
 & EP1101
 Akyol, O EP178
 Al Emadi, B EP647
 Al Hindi, H EP647
 Al Zaydi, M EP513
 Alaarg, A EP195
 Alacid, CM EP69
 Alagoz, E EP1087
 & EP380
 Alam, MM EP311
 Al-Amin, M GP84
 Alaminos-Castillo, MA
 EP807, EP811
 & EP834
 Alapi, T EP587
 Albani, A EP736
 Albert, L EP799 & GP13
 Albu, SE EP134A
 Alcaide, J EP803 & EP823
 Alcaide-Torres, J EP168,
 EP224, EP783 & OC7.1
 Alcazar, V EP1118
 Alcántara, C EP656
 Aldahmani, KM EP166
 Alekna, V EP112
 Aleknaite, I EP112
 Aleksandrov, Y EP399,
 EP982 & EP983
 Alevizaki, M EP874,
 EP973 & GP237
 Alevizaki, M
 Alexaki, S EP1126
 Alexander, E S1.1
 Alexandra Hanzu, F
 GP124
 Alexandra, N EP268
 Alexandraki, K EP618,
 EP633 & GP23
 Alexandru Niculescu, D
 EP1066
 Alexeev, D EP451
 Alexescu, T EP828
 Alexiadou, A EP1129
 Alexiou, I EP436 & EP442
 Alfredo Martinez, J OC12.3
 Alhambra Exposito, MR
 EP753
 Alhambra-Exposito, MR
 EP757
 Al-Hashimi, A EP1128
 Alhusuny, A EP513
 & EP839
 Ali Acar, E EP66
 Ali Kasifoglu, M GP83
 Ali, O EP523
 Ali Raza Kazmi, S EP228
 & EP519
 Ali Tam, A EP1135,
 GP209 & GP233
 Alikasifoglu, M EP646
 Alimehmeti, M EP1142
 Alimova, K EP762
 & EP763
 Alio Lavín Gómez, B
 EP979 & GP11
 Alioglu, B EP524
 Alissa, E EP242
 Alkaabi, FM EP100
 & EP166
 Alkan, A EP1099 &
 GP209
 Alkan, G EP496
 Alkebro, C GP167
 Alla, L EP237
 Allelein, S OC14.5
 Allende, F GP148
 Allendorf, I GP40
 Aller, J EP1118
 Allo, G EP107 & EP319
 Alloisio, M GP111
 Allolio, B GP116
 Almaden, Y EP144
 Almasri, MS EP1004
 Almazrouei, RA EP100
 & EP166
 Almeida, L EP793
 Almeida, R EP31
 Almeida, RC EP346

- Ritzel, K OC7.3
 Riva, E EP612 & EP865
 Rivas-Rivas, M EP213
 Rivezzi, M EP583
 Riviere, L-D GP161
 Rizk-Rabin, M GP116 & OC2.4
 Rizou, A EP772
 Rizov, C EP1048
 Rizvi, SSR EP468 & EP717
 Rjeb, O EP978
 Roa, J EP789 & GP127
 Roa Llamazares, C EP120
 Robbins, R EP414
 Robert, C EP6
 Roberts, G EP657
 Robledo, M EP247
 Robles, J-P EP861
 Roca-Rodríguez, M GP76
 Rocha, DRTW EP392
 Rocha, R EP334
 Rochfort, K EP215
 Rochira, V EP146 & EP718
 Rodermund, L GP190
 Rodondi, N S11.2
 Rodríguez Berrocal, V EP1134
 Rodríguez, IPD EP336
 Rodríguez, NOD EP336
 Rodríguez, O EP210
 Rodríguez-Abreu, D GP216
 Rodríguez-Cañete, A EP804
 Rodríguez-Morata, A EP803
 Rodríguez-Perálvarez, M GP131
 Rodríguez-Ramos, C EP213
 Rodrigues, A EP334
 Rodrigues, D EP115, EP121, EP175, EP338, EP75, EP813, EP818 & GP92 & GP207
 Rodrigues, E EP1104, EP722 & GP59
 Rodrigues, F OC14.4
 Rodrigues, J EP177
 Rodrigues, M EP279
 Rodrigues Marques, R GP203
 Rodriguez, M GP144
 Rodriguez, NC EP557
 Rodriguez, R EP885
 Rodriguez-Cañete, A EP807 & EP834
 Rodriguez-Morata, A EP823
 Rodriguez-Ortiz, ME GP144
 Rodriguez-Pacheco, F EP807, EP811 & EP834
 Rogatko, I EP751
 Rohr, A GP130
 Rojas, D GP145
 Rojas Martelo, G EP1134
 Rojas, R EP1037
 Roji, AM EP117
 Rojo, G EP557
 Rolinski, J GP195
 Rolo, F EP964
 Roman, AC EP1102
 Romaní, M EP743
 Romanelli, F EP957
 Romano, A GP172
 Romero, J EP142
 Romero, SG EP911
 Romero-Gómez, M EP213
 Romijn, J S7.1
 Río-Moreno, Md GP131
 Romualdi, D EP694
 Ronchi, C EP15, OC1.1 & OC1.2
 Ronchi, C GP116
 Ronchi, CL OC2.3
 Ronkainen, K EP203
 Roomp, K GP7
 Roque, C EP1005, EP258, EP635 & GP63
 Rosa Alhambra-Expósito, M EP764
 Rosario Acampado, L GP204
 Rosciolesi, DV EP1102
 Rose-John, S OC5.4
 Rosendo, C GP76
 Rosenfeld, RG EP845 & GP139
 Rosmarin, M EP1012
 Ross, IL EP56
 Ross, R EP14 & OC5.3
 Rossetto, R EP1094
 Rossi, F GP136
 Rossi, G EP883
 Rostomyan, L EP889
 Roszkowska-Purska, K EP593
 Rotariu, D EP304
 Rotermund, R EP899
 Rouabhi, S EP671
 Roughton, M GP153
 Roumeliotaki, T EP136
 Rousset, B GP235
 Roussou, P EP890 & EP906
 Rovira, E OC14.4
 Roy, M EP84
 Roy, P GP235
 Rozhinskaia, L EP341
 Rozhinskaya, L EP13, EP151, EP379, EP625 & EP99
 Rozhynskaya, L EP596
 Réti, Z EP1052
 Rützi, S OC3.2
 Ruano, MAD EP336
 Rubin, B OC1.1
 Rubini, C EP591
 Rubino, M GP230
 Rubio, E EP557
 Rubio, O EP1010 & EP1011
 Ruchala, M EP1022 & EP614
 Ruchala, M EP1073, EP1100, EP202 & EP606
 Rudakova, J EP483
 Rudovich, N OC12.3
 Rudser, K GP36
 Rui Mascarenhas, M EP257
 Ruiz de Azua, T EP1133
 Ruiz, MCG EP168
 Ruiz Ochoa, D EP979 & GP11
 Ruiz-Gines, MA GP199
 Ruiz-Gracia, T EP38 & EP754
 Ruiz-Pino, F EP789 & GP127
 Rump, LC EP5 & GP9
 Rumpler, M EP546
 Rungby, J EP25
 Runkle de la Vega, I EP760
 Runkle, I EP38 & EP754
 Rurale, G GP171
 Russo, D EP863
 Rusu, C EP371
 Ruthishauser, J GP155
 Rutkowska, J EP19, EP416 & EP422
 Rutz, S EP621
 Ruza, I EP502
 Ryan, M GP16
 Rychlik, S GP208
 Ryes, AG GP54
 Ryhänen, EM EP138
 Rylander, L EP741
 Ryu, J EP1093
 Rzepka, E EP280 & EP96
 Saad, F EP204 & GP187
 Saad, G EP179
 Saad, H EP613
 Saatov, T EP437
 Saavedra, A EP1104, EP328, EP722, EP793, EP817 & GP59
 Saavedra, A GP142
 Saba, A EP137
 Sabah, M EP1122
 Sabino, F EP554
 Sabino, T EP643 & EP925
 Sacchetti, A D1.3
 Sachs, S GP52
 Šwider, G EP924
 Świrska, J EP335
 Sadiku, E EP505
 Saed, M EP515
 Saeedi, P EP839
 Saeger, W OC9.5
 Safi, A EP311
 Saglam, B EP1032 & EP524
 Saglam, F EP1021 & EP1050
 Saglar, E EP405, EP409, EP420 & EP445
 Sahin, AB EP1162 & EP36
 Sahin, I EP826 & EP995
 Sahin, M EP975
 Sahin, T EP1009
 Sahinoglu-Keskek, N GP89
 Said, A EP309
 Saida, F EP470, EP471, EP791 & EP815
 Saidnazirkhanova, M EP709 & EP761
 Saini, S EP666
 Sainsbury, C EP411
 Sakali, A-K EP782
 Sala, E EP3
 Salah, DB EP1007
 Salam, R EP476
 Salas, C GP66
 Salas, RO GP112
 Salavessa, J EP656
 Salem, H GP82
 Salem, LB EP186, EP325, EP692 & EP698
 Salenave, S EP1057
 Salenave, S GP163
 Saler, T GP89
 Salihoglu, M GP72
 Salinas, CS EP398
 Saltiki, K EP973 & GP237
 Salvatierra, J GP112
 Salvesen, H GP172